Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 | M – CDC March 7, 2024
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024 | M – CDC March 7, 2024
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION an – CDC February 29, 2024
Vaccine effectiveness: Which COVID-19 shots are most protective against severe disease? – Medical Xpress February 2, 2024
Effectiveness of Nirmatrelvir–Ritonavir Against the Development of Post–COVID-19 Conditions Among U.S. Veterans: A Target Trial Emulation: Annals of Internal Medicine: Vol 0, No 0 – Annals of Internal Medicine October 30, 2023
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study – The Lancet April 13, 2023
Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis – The BMJ March 22, 2023
FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and aggressive form of the disease – CNBC March 22, 2023
Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023 | MMWR – CDC February 16, 2023
Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans January 3, 2023January 2, 2023